Allogenic stem cell transplantation following non-myeloablative conditioning regimens as adoptive immunotherapy in patients with hematological malignancies

Medical Science Monitor

Volumn 8, Issue 10, 2002, Pages

  Busca, Alessandro ^a   Bruno, Benedetto ^a   Boccadoro, Mario ^a   Locatelli, Franco ^a   Falda, Michele ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Allogenic stem cell transplantation; Graft versus leukemia effect; Mixed chimerism; Non myeloablative regimens

Indexed keywords

BUSULFAN; CARMUSTINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; IDARUBICIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; PURINE DERIVATIVE; THIOTEPA; THYMOCYTE ANTIBODY; ALKYLATING AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; BONE MARROW TOXICITY; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; IRRADIATION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PERIPHERAL BLOOD STEM CELL; REVIEW; TREATMENT INDICATION; WHOLE BODY RADIATION; ANIMAL; BONE MARROW; CHEMISTRY; HISTOCOMPATIBILITY; IMMUNOLOGY; LEUKEMIA; METABOLISM; METHODOLOGY; PATHOLOGY; RADIATION EXPOSURE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THYMUS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; PURINES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THIOTEPA; THYMUS GLAND; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036776154     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Frei EI, Canellos G: Dose: A critical factor in cancer chemotherapy. Am J Med, 1980; 69: 585-594
2. Gratwohl A, Hermans J, Pearce R et al: Haematopoietic precursor cell transplants, main risk factors. Blood, 1995; 86: 618a
3. Molina AJ, Storb R: Hematopoietic stem cell transplantation in older adults. In: Rowe J, Lazarus H, Carella AM, editors. Bone Marrow Transplantation Annual. London, UK: Martin Dunitz Limited; 2000: 111-137
4. Sullivan KM, Storb R, Buckner CD et al: Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. New Engl J Med, 1989; 320: 828-834
5. Bertz H, Burger JA, Kunzmann R, Finke J: Adoptive immunotherapy for relapsed multiple myeloma after allogenic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect. Leukemia, 1997; 11: 281-283
6. Van Besien KM, de Lima M, Giralt SA et al: Management of lymphoma recurrence after allogenic transplantation: The relevance of graft-versus-lymphoma effect. Bone Marrow Transplant, 1997; 19: 977-982
7. Weiden PL, Flournoy N, Thomas ED et al: Antileukemic effect of graft versus host disease in recipients of allogenic marrow grafts. New Engl J Med, 1979; 300: 1068-1073
8. Horowitz MM, Gale RP, Sondel PM et al: Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood, 1990; 75: 555-562
9. Kolb HJ, Schattenberg A, Goldman JM et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Enropean Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood, 1995; 86: 2041-2050
10. Mendigers CM; Meijerink JP, Raemaekers J M, Schattenberg AV, Mensink EJ: Graft-versus-lymphoma effect of donor leukocyte infusion shown by real-time quantitative PCR analysis of t (14:18). Lancet, 1998; 352: 1522-1523
11. Rondon G, Giralt S, Huh Y et al: Graft-versus-leukemia effect after allogenic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant, 1996; 18: 669-675
12. Cobbold SP, Martin G, Qin S, Waldmann H: Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature, 1986; 323: 164-166
13. Sykes M, Szot GL, Swenson KA, Pearson DA: Induction of high levels of allogenic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med, 1997; 3: 783-787
14. Koch U, Korngold R: A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers. Blood. 1997; 89: 2880-2890
15. Andrews RG, Winkler A, Potter J, Bryant E, Knitter GH, Bernstein ID, Ochs HD: Normal immunologic response to a neoantigen, bacteriophage phiX-174, in baboons with long-term lymphohematopoietic reconstitution from highly purified CD34+Lin- allogenic marrow cells. Blood, 1997; 90: 1701-1708
16. Storb R, Epstein RB, Rudolph RH, Thomas ED: Allogenic canine bone marrow transplantation following cyclophosphamide. Transplantation, 1969; 7: 378-284
17. Storb R, Weiden PL, Graham TC, Lerner KG, Nelson N, Thomas ED: Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum. Transplantation, 1977; 24: 349-355
18. Bruno B, Nash RA, Wallace PM, Gass MJ, Thompson J, Storb R, McSweeney A: CD34+ selected bone marrow grafts are radioprotective and establish mixed chimerism in dogs given high close total body irradiation. Transplantation, 1999; 68: 338-344
19. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, Leisenring W, Shulman H: Stable mixed hematopoietic chimerism in DLA-identical littermate clogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood, 1997; 89: 3048-3054
20. Yu C, Storb R, Mathey B et al: DLA-identical bone marrow grafts after low-dose total body irradiation: Effects of high-dose corticosteroids and cyclosporine on engraftment. Blood. 1995; 86: 4376-4381
21. Pelot MR, Pearson DA, Swenson K et al: Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease. Biol Blood Marrow Transplant, 1999; 5: 133-143
22. Sykes M, Sheard MA, Sachs DH: Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med, 1988; 168: 2391-2396
23. Georges GE, Storb R, Brunvand MW, Kiem HP, Moore PF, Malik P, Ennist D, Nash RA: Canine T cells transduced with a herpes simplex virus thymidine kinase gene: A model to study effects on engraftment and control of graft-versus-host disease. Transplantation, 1998; 66: 540-544
24. Slavin S, Nagler A, Naparstek E et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 1998; 91: 756-763
25. Giralt S, Estey E, Albitar M et al: Engraftment of allogenic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood, 1997; 89: 4531-4536
26. Giralt S, Thall PF, Khouri I et al: Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogenic progenitor cell transplantation. Blood, 2001; 97: 631-637
27. Giralt S, Weber D, Aleman A et al: Non myeloablative conditioning with fludarabine/melphalan (FM) for patients with multiple myeloma (MM). Blood, 1999; 94 (suppl 1): 1549
28. Khouri IF, Keating M, Korbling M et al: Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogenic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Journal Clin Oncol, 1998; 16: 2817-2824
29. Khouri F, Saliba RM, Girault S et al: Nonablative allogenic haematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood, 2001; 98: 3595-3599
30. Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J: Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogenic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect. Journal Clin Oncol, 1999; 17: 2044-2049
31. Sykes M, Preffer F, McAfee S et al: Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet, 1999; 353: 1755-1759
32. Spitzer TR, McAfee S, Sackstein R et al: Intentional induction of mixed chimerism and achievement of anti-tumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory haematological malignancies. Biol Blood Marrow Transplant, 2000; 6: 309-320
33. Raiola AM, Van Lint MT, Lamparelli T et al: Reduced intensity thiotepa-cyclophosphamide conditioning for allogenic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol, 2000; 109: 716-721
34. Busca A, Bosi A, Van Lint MT et al: Transplant-related mortality (TRM) in patients receiving reduced versus conventional intensity thiotepa-cyclophosphamide (THIO-CY) conditioning: The impact of stem cell source in 176 consecutive patients allografted from HLA-identical siblings. Bone Marrow Transplantation, 2001; 27 (suppl 1); S282
35. Carella AM, Lerma E, Dejana A et al: Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica. 1998; 83: 904-909
36. Carella AM, Cavaliere M, Lerma E et al: Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogenic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol, 2000; 18: 3918-3924
37. McSweeney PA, Niederwieser D, Shzuru JA et al: Hemapoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effect. Blood, 2001; 97: 3390-3400
38. Sandmaier BM, Maloney DG, Gooley T et al: Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: Clinical results of a TBI-based conditioning regimen. Blood. 2001; 98: 742a
39. Maris MB, Sandmaier BM, Niderwieser D et al: The effect of donor lymphocyte infusions (DLI) on chimerism and persistent disease after nonmyeloablative hematopoietic stem cell transplant (HSCT). Blood, 2000; 96: 777a
40. Anderlini P, Giralt S, Andersson B et al: Allogenic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant, 2000; 26: 615-620
41. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R: Allogenic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant, 2000; 25: 1021-1028
42. Badros A, Barlogie B, Morris C et al: High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood, 2001; 97: 2574-2579
43. Garban F, Attal M, Payen Rossi JF, Payen C, Fegueux N, Sotto JJ: Immunotherapy by non-myeloablative allogenic stem cell transplantation in multiple myeloma: Results of a pilot study as salvage therapy after autologous transplantation. Leukemia, 2001; 15: 642-646
44. Maloney DG, Sahebi F, Stockerl-Goldstein KE, et al: Combining an allogenic graft-versus-myeloma effect with high dose autologous stem cell rescue in the treatment of mutliple myeloma. Blood, 2001; 98: 1822a
45. Bruno B, Ladetto M, Maloney D, et al: Molecular Remission in Multiple Myeloma After Non Myeloablative Allogenic Hematopoietic Cell Transplantation: Proof of Principle. Submitted
46. Giralt S: Updates on unrelated donor transplantation, donor lymphocyte infusions, and non-ablative stem cell transplantation. ASH Educational Program Book 2000, pp 97-101
47. Bornhauser M, Kiehl M, Siegert W et al: Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: A retrospective analysis. Br J Haematol, 2001; 115: 119-124
48. Slavin S: Treatment of myeloid leukemias with non-myeloablative stem cell transplantation: accomplishments and future goals. Hematology 2000 ASH Educational Program Book, pp 81-89
49. Bornhauser M, Kroschinsky F, Schaekel U et al: Dose reduced conditioning and allogenic stem cell transplantation in 34 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Blood, 2000; 96: 3375a
50. Kroger N, Schetelig J, Zabelina T et al: A fludarabine-based dose-reduced conditioning regimen followed by allogenic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant, 2001; 28: 643-647
51. Michallet M, Archimbaud E, Bandini G et al: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med. 1996; 124: 311-315
52. Chakraverty R, Peggs K, Chopra R et al: Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 2002; 99: 1071-1078
53. Savage WJ, Bleesing JJH, Douek D et al: Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism. Bone Marrow Transplant, 2001; 28: 463-471
54. Friedman TM, Varadi G, Hopely DD et al: Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogenic matched unrelated bone marrow transplantation compared to myeloablative approaches. Biol Blood Marrow Transplant, 2001; 7: 656-664
55. Bahceci E, Epperson D, Patibindla A et al: Rapid reconstitution of T cell compartment after non myeloablative allogenic stem cell transplantation (NMAT). Blood, 1999; 97 (Suppl.): 134a
56. Mohty M, Faucher C, Vey N et al: High rate of secondary viral and bacterial infections in patients undergoing allogenic bone marrow mini-transplantation. Bone Marrow Transplant, 2000; 26: 251-255
57. Hermann S, Klein SA, Jacobi V et al: Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens. Br J Haematol, 2001; 113: 446-454
58. Martino R, Caballero MD, Canals C et al: Reduced-intensity conditioning reduces the risk of severe infections after allogenic peripheral blood stem cell transplantation. Bone Marrow Transplant, 2001; 28: 341-347
59. Mossad SB, Avery RK, Longworth DL et al: Infectious complications within the first year after nonmyeloablative allogenic peripheral blood stem cell transplantation. Bone Marrow Transplantant, 2000; 28: 491-495
60. Kottaridis PD, Milligan DW, Chopra R et al: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood, 2000; 96: 2419-2425
61. Bornhauser M, Thiede C, Schuler U et al: Dose-reduced conditioning for allogenic blood stem cell transplantation: Durable engraftment without antithymocyte globulin. Bone Marrow Transplant, 2000; 26: 119-125
62. Craddock C, Bardy P, Kreiter S et al: Engraftment of T-cell-depleted allogenic haematopoietic stem cells using a reduced intensity conditioning regimen. Br J Haematol, 2000; 111: 797-800
63. Mackinnon S, Papadopoulos EB, Carabasi MH et al: Adoptive immunotherapy evaluating escalating closes of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood, 1995; 86: 1261-1268
64. Champlin R, Ho W, Gajewski J et al: Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogenic bone marrow transplantation. Blood, 1990; 76: 418-423
65. Corradini P, Bregni M, Tarella C et al. Allografting for high-risk hematological and solid tumors: Reduced intensity chemotherapy followed by the reinfusion of lymphocytes engineered with timidine kinase (TK) gene. Bone Marrow Transplant, 2000; 25 (Suppl 1): 396
66. Bonini C, Ferrari O, Verzeletti S et al: HSV-TK gene transfer into donor lymphocytes for control of allogenic graft-versus-leukemia. Science, 1997; 276: 1719-1724
67. Maris M, Niederwieser D, Sandmaier B et al: Nonmyeloablative hematopoietic stem cell transplant (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT. Blood. 2001; 98: 858a
68. Childs R, Chernoff A, Contentin N et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogenic peripheral-blood stem-cell transplantation. New Engl J Med, 2000; 343: 750-758
69. Mohty M, Fegueux N, Exbrayat G et al: Enhanced graft-versus-tumor effect following dose-reduced conditioning and allogenic transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplant, 2001; 28: 335-339
70. Grigg A, Bardy P, Byron K et al: Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant, 1999; 23: 107-110
71. Wasch R, Reisser S, Hahn J et al: Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogenic transplantation. Bone Marrow Transplant, 2000; 26: 243-250
72. Martino R, Caballero MD, Canals C et al: Allogenic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results of a prospective multicentre study. Br J Haematol, 2001; 115: 653-659.